Shire, the London-listed pharmaceuticals group, has moved to bolster its rare disease treatment business with the $4.2bn acquisition of ViroPharma. Ireland-domiciled Shire will pay $50 a share in cash ...
Brokers forecast strong growth but share price has been flat ...
Five at Five: FTSE 100 powers on to new record, Trump sweeps away Biden regime, Meme coin makes him billions, House prices soar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback